Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Allon receives approval for phase II clinical trial in Alzheimer-related condition
January 29th, 2007
Allon Therapeutics, Inc., (NPC), The Neuro Protection Company, announced IRB (Institutional Review Board) approval to begin enrolling patients for a phase II human clinical trial evaluating the company's lead product AL-108. The trial will evaluate the efficacy of AL-108 in improving cognitive function in patients who suffer from Mild Cognitive Impairment (MCI), often a pre-cursor to Alzheimer disease. Gordon McCauley, president and CEO of Allon, said the phase II trial is an important next step in determining the effectiveness of AL-108 as a treatment for Alzheimer disease. It has been estimated that 85% of people diagnosed with MCI develop...
Source: Biotech Business Week (2007-01-29)
|
